| Literature DB >> 31594975 |
Rafał Bielas1, Anna Mielańczyk1, Magdalena Skonieczna2,3, Łukasz Mielańczyk4, Dorota Neugebauer5.
Abstract
New type of carriers based on grafted poly(ionic liquid)s was designed for delivery of ionically attached salicylates (Sal). Choline derived ionic liquid monomeric units were successfully introduced with various content in the side chains by the controlled radical polymerization. Properly high amounts of ionic pharmaceutics in the polymer systems were achieved by the well-fitted length and grafting degree of the side chains. In aqueous solution the graft copolymers were self-assembled into the spherical superstructures with sizes up to 73 nm. Delivery studies showed "burst" release within 4 h, after that it was slower yielding ~70% of released drug within 80 h. Proposed nanocarriers supported low toxicity against human cells (NHDF and BEAS-2B), anti-inflammation activity evaluated with the use of pro-inflammatory interleukins (IL-6 and IL-8) and antibacterial activities towards E. coli. Adjustment of ionic drug content by structural parameters of graft copolymers, including grafting degree and graft length, are advantageous to tailor nanocarriers with self-assembly properties in aqueous media. Effective release process by ionic exchange and biological activity with low toxicity are promising for further development of this type of drug delivery (DDS).Entities:
Mesh:
Substances:
Year: 2019 PMID: 31594975 PMCID: PMC6783615 DOI: 10.1038/s41598-019-50896-5
Source DB: PubMed Journal: Sci Rep ISSN: 2045-2322 Impact factor: 4.379
Characterization of macroinitiators (Ia, IIa, IIIa) and their precursors (I–III).
| No | [HEMA]0 (mol%) | Monomer conversiona (%) | DPa | Mnb (g/mol) | Ðb | HEMA or BIEMa (mol%) |
|---|---|---|---|---|---|---|
|
| 25 | 57 | 342 | 36500 | 1.52 | 22 |
|
| — | — | 342 | 47700 | 1.61 | 22 |
|
| 50 | 33 | 198 | 23000 | 1.39 | 53 |
|
| — | — | 198 | 38600 | 1.68 | 53 |
|
| 75 | 46 | 276 | 33200 | 1.44 | 67 |
|
| — | — | 276 | 60750 | 1.87 | 67 |
Conditions for I–III: [HEMA + MMA]0:[EBiB]0:[CuBr]0:[dNbpy]0 = 600:1:1:2, monomer:anisol ratio 10:1, temperature 60 °C; Ia, IIa and IIIa: bromoesterification of hydroxyl groups in copolymers I, II and III, respectively (pyridine, rt, stirred overnight); adetermined with 1H NMR, where DP is degree of polymerization, bdetermined with SEC (THF, polystyrene calibration), where Mn is number average molecular weight of polymer, Ð polymer dispersity.
Figure 1Synthesis of ionic graft copolymers.
Characteristics of Cl contained graft copolymers.
| No. | Time (h) | XMa (%) | DPsca | FChMA/Cla (mol%) | nsca | Mn (g/mol) | Ðb | dhc (nm) | CMC (mg/mL) |
|---|---|---|---|---|---|---|---|---|---|
|
| 1 | 5 | 20 | 25 | 75 | 235000 | 1.26 | 18 | 0.005 |
|
| 2 | 13 | 50 | 25 | 524450 | 1.32 | 22 | 0.005 | |
|
| 3 | 19 | 75 | 25 | 706300 | 1.35 | 23 | 0.0005 |
Conditions: [ChMA/Cl + MMA]0:[Ia]0:[CuCl]0:[bpy]0 = 100 + 300:1:1:2, methanol:THF 1:1, where methanol:ChMA/Cl = 1 ml:1 g, 40 °C; adetermined with NMR, where XM is monomer conversion, DPsc polymerization degree of side chains, FChMA/Cl is content of ChMA/Cl in side chains, nsc number of side chains, bdetermined with SEC (THF, polystyrene calibration), where Mn is number average molecular weight of polymer, Ð polymer dispersity, cdetermined with a DLS, where dh is hydrodynamic diameter; CMC is critical micellization concentration.
Characterization of Sal contained graft copolymers.
| No. | fChMA/Sal (mol%) | Time (h) | XMa (%) | DPsca | FChMA/Sala (mol%) | MI/nsca | Mn (g/mol) | Ðb | dhc (nm) | CMC (mg/mL) |
|---|---|---|---|---|---|---|---|---|---|---|
|
| 25 | 0.5 | 34 | 17 | 29.4 | 243500 | 1.04 | 60 | 0.005 | |
|
| 1 | 48 | 24 | 25.0 | 324000 | 1.04 | 28 | — | ||
|
| 50 | 0.5 | 12 | 6 | 66.7 | 151400 | 1.04 | 73 | — | |
|
| 1.5 | 24 | 12 | 66.7 | 256300 | 1.04 | 56 | — | ||
|
| 75 | 0.5 | 22 | 11 | 90.9 | 282300 | 1.05 | 48 | — | |
|
| 3 | 56 | 28 | 71.4 | 568800 | 1.1 | 51 | 0.01 | ||
|
| 25 | 0.5 | 32 | 16 | 25.0 | 289300 | 1.05 | 16 | — | |
|
| 3 | 74 | 37 | 21.6 | 603300 | 1.2 | 15 | — | ||
|
| 50 | 0.5 | 16 | 8 | 50.0 | 216100 | 1.05 | 26 | — | |
|
| 1 | 24 | 12 | 50.0 | 303500 | 1.06 | 16 | — | ||
|
| 75 | 0.5 | 12 | 6 | 83.3 | 205800 | 1.04 | 17 | — | |
|
| 3 | 78 | 39 | 74.4 | 1086000 | 1.06 | 22 | — | ||
|
| 25 | 0.5 | 22 | 11 | 27.3 | 380900 | 1.14 | 24 | — | |
|
| 3 | 78 | 39 | 20.0 | 1171200 | 1.45 | 56 | 0.005 | ||
|
| 50 | 0.5 | 22 | 11 | 36.4 | 419700 | 1.35 | 29 | — | |
|
| 3 | 78 | 39 | 33.3 | 1287600 | 1.87 | 33 | — | ||
|
| 75 | 0.5 | 22 | 11 | 63.6 | 554700 | 1.05 | 35 | — | |
|
| 3 | 86 | 43 | 74.4 | 2099100 | 1.28 | 40 | 0.005 |
Conditions: [ChMA/Sal + MMA]0:[MI]0:[CuCl]0:[bpy]0 = 50:1:0.5:1, methanol:THF 1,5:1, where methanol:ChMA/Sal = 2.5 ml:1 g, rt; fChMA/Sal is initial content ChMA/Sal; adetermined with NMR, where X is monomer conversion, DPsc polymerization degree of side chains, FChMA/Sal content of ChMA/Sal in side chains, nsc number of side chains, bdetermined with SEC (DMF, polystyrene calibration), where Mn is number average molecular weight of polymer, Ð polymer dispersity, cdetermined with DLS, where dh is hydrodynamic diameter; CMC is critical micellization concentration, - means not determined.
Figure 2Weight ratio of salicylate to graft polymer matrix.
Figure 3Histograms of particles formed by chloride (IV) and salicylate (VIIa) containing graft copolymers with comparable DG and anion content for 0.5 mg/mL concentration in deionized water at 25 °C.
Figure 4TEM analysis of graft copolymer XIVb.
Figure 5Salicylate release profiles for selected graft copolymers in PBS pH 7.4 at 38 °C, number of repetitions is 3.
Figure 6Relative viabilities: 10 × 103 of BEAS-2B (A) and NHDF (B) cells seeded in respective medium incubated with PBS solutions of the selected graft copolymers and control NaSal in 96-well microtiter plates in a humidified atmosphere containing 5% CO2 at 37 °C for 72 h.
Figure 7Relative viabilities: inoculum about 2.5 × 103 cells/ml of E. coli in respective medium incubated with PBS solutions of the selected graft copolymers in 96-well microtiter plates at 37 °C for 24 h.
Figure 8Relative gene expression level, for pro-inflammatory IL 6 and IL 8 cytokines in BEAS-2B cells after 72 h of incubation [R = 2−∆∆Ct]. NaSal at dose of 2.5 µg/ml was used as additional control.